Presentation COVID-19: Treatment and Prophylaxis Strategies

Article Structural Pathways to Developing Vaccines against Novel Cor...

A- Treatment by DNA

https://scitechdaily.com/clues-to-covid-19-treatment-from-dna-of-patients-with-severe-forms-of-coronavirus-disease/

Why Does Covid-19 Make Some People So Sick? Ask Their DNA

https://www.wired.com/story/why-does-covid-19-make-some-people-so-sick-ask-their-dna/

B- Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study

https://www.drugs.com/clinical_trials/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273-phase-1-study-18461.html

C- Is infusions of antibody-rich plasma from other patients who have had the disease and recovered effected? Convalescent plasma therapy

Warning: Thrombosis may occur with immune globulin intravenous (IGIV) products, including immune globulin-ifas. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. Immune globulin-ifas does not contain sucrose.For patients at risk of thrombosis, renal dysfunction, or renal failure, administer immune globulin-ifas at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

https://www.drugs.com/sfx/immune-globulin-intravenous-side-effects.html

Article Detection of SARS-CoV-2 by RT-PCR in anal from patients who ...